Lucy Scientific Discovery Inc. Unveils New Sleep Aid Product: Twilight by Lucy
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (NASDAQ: LSDI),…
Month: July 2023
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs CINCINNATI,…
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs CINCINNATI,…
NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment MALVERN, Pa., July 11, 2023…
NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment MALVERN, Pa., July 11, 2023…
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed…
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed…
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company BASKING…
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company BASKING…
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
— Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of…
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
— Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of…
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader…
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader…
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine’s Scientific Advisory Board
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE:…
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine’s Scientific Advisory Board
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE:…
McClintock and Amfora Form Strategic Collaboration to Leverage AI to Improve Protein Content of Soy
SAN FRANCISCO, July 11, 2023 (GLOBE NEWSWIRE) — Artificial intelligence and machine learning innovator McClintock…
McClintock and Amfora Form Strategic Collaboration to Leverage AI to Improve Protein Content of Soy
SAN FRANCISCO, July 11, 2023 (GLOBE NEWSWIRE) — Artificial intelligence and machine learning innovator McClintock…
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to…